Threadneedle Asset Mgmt Hldgs Ltd Form 8.3 - Horizon Therapeutics Plc (3083I)
01 12월 2022 - 11:02PM
UK Regulatory
TIDMTTM TIDM0A2V
RNS Number : 3083I
Threadneedle Asset Mgmt Hldgs Ltd
01 December 2022
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF
THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Threadneedle Asset Management Holdings Ltd (on behalf of
affiliate companies that carry on
(a) Full name of discloser the business of fund and portfolio management)
(b) Owner or controller of interests and short
positions disclosed, if different from 1(a)
The naming of nominee or vehicle companies is Ameriprise Financial, Inc. ultimate parent company of
insufficient. For a trust, the trustee(s), Threadneedle Asset Management Holdings
settlor and beneficiaries must be named. Ltd and affiliated companies.
----------------------------------------------------------
(c) Name of offeror/offeree in relation to whose
relevant securities this form relates
Use a separate form for each offeror/offeree Horizon Therapeutics plc
----------------------------------------------------------
(d) If an exempt fund manager connected with an
offeror/offeree, state this and specify identity
of offeror/offeree (Note 1)
----------------------------------------------------------
(e) Date position held/dealing undertaken
For an opening position disclosure, state the
latest practicable date prior to the disclosure 29(th) November 2022
----------------------------------------------------------
(f) In addition to the company in 1(c) above, is No
the discloser also making disclosures in
respect of any other party to the offer?
If it is a cash offer or possible cash offer, state
"N/A"
----------------------------------------------------------
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more
than one class of relevant securities of the offeror or offeree
named in 1(c), copy table 2 for each additional class of relevant
security.
Ap28
Interests and short positions in the relevant securities of the
offeror or offeree to which the disclosure relates following the
dealing (if any)
(Note 2)
Class of relevant security
(Note 3) $0.0001 ordinary shares
Interests Short positions
------------------ -----------------
Number % Number %
----------- ----- -------------
(1) Relevant securities owned and/or controlled 2,529,983 1.12
----------- ----- -------------
(2) Cash-settled derivatives
----------- ----- -------------
(3) Stock-settled derivatives (including options) and agreements to purchase/
sell
----------- ----- -------------
Total 2,529,983 1.12
----------- ----- -------------
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new
securities and any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant Purchase/sale Number of Price per unit
security securities (Note 5)
$0.0001 ordinary shares Sale 42 USD 78.76
-------------- ------------ ---------------
$0.0001 ordinary shares Purchase 255 USD 78.77
-------------- ------------ ---------------
Ap29
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price
relevant description e.g. opening/ closing a long/ short position, increasing/ reference per unit
security e.g. CFD reducing a long/ short position securities (Note 5)
(Note 6)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, purchasing, Number Exercise Type Expiry Option
relevant description e.g. selling, varying of price per e.g. date money
security call etc. securities unit American, paid/
option to which European received per unit
option etc.
relates
(Note 6)
(ii) Exercise
Class of Product Exercising/ Number of Exercise
relevant description exercised securities price per
security e.g. call against unit
option (Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of Nature of dealing Details Price per unit (if
relevant e.g. subscription, applicable)
security conversion, exercise (Note 5)
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement,
or any agreement or understanding, formal
or informal, relating to relevant securities
which may be an inducement to deal or
refrain from dealing entered into by
the person making the disclosure and
any party to the offer or any person
acting in concert with a party to the
offer.
Irrevocable commitments and letters
of intent should not be included. If
there are no such agreements, arrangements
or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement
or understanding between the person disclosing
and any other person relating to the
voting rights of any relevant securities
under any option referred to on this
form or relating to the voting rights
or future acquisition or disposal of
any relevant securities to which any
derivative referred to on this form is
referenced. If none, this should be stated.
None
(c) Attachments
Is a Supplemental Form 8 attached? NO
Date of disclosure 01/12/2022
Contact name Ben Lyon
--------------
Telephone number +441793 363754
--------------
Public disclosures under Rule 8.3 of the Rules must be made to a
Regulatory Information Service.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEXFLFBLLLEFBD
(END) Dow Jones Newswires
December 01, 2022 09:02 ET (14:02 GMT)
Sanofi (LSE:0A2V)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Sanofi (LSE:0A2V)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
